[go: up one dir, main page]

RU2019118261A3 - - Google Patents

Download PDF

Info

Publication number
RU2019118261A3
RU2019118261A3 RU2019118261A RU2019118261A RU2019118261A3 RU 2019118261 A3 RU2019118261 A3 RU 2019118261A3 RU 2019118261 A RU2019118261 A RU 2019118261A RU 2019118261 A RU2019118261 A RU 2019118261A RU 2019118261 A3 RU2019118261 A3 RU 2019118261A3
Authority
RU
Russia
Application number
RU2019118261A
Other versions
RU2762573C2 (ru
RU2019118261A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60452703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019118261(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2019118261A publication Critical patent/RU2019118261A/ru
Publication of RU2019118261A3 publication Critical patent/RU2019118261A3/ru
Application granted granted Critical
Publication of RU2762573C2 publication Critical patent/RU2762573C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019118261A 2016-11-15 2017-11-14 Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 RU2762573C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662422144P 2016-11-15 2016-11-15
US62/422,144 2016-11-15
US201762479391P 2017-03-31 2017-03-31
US62/479,391 2017-03-31
PCT/IB2017/057097 WO2018092020A1 (en) 2016-11-15 2017-11-14 Dose and regimen for hdm2-p53 interaction inhibitors

Publications (3)

Publication Number Publication Date
RU2019118261A RU2019118261A (ru) 2020-12-17
RU2019118261A3 true RU2019118261A3 (ru) 2021-03-18
RU2762573C2 RU2762573C2 (ru) 2021-12-21

Family

ID=60452703

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019118261A RU2762573C2 (ru) 2016-11-15 2017-11-14 Доза и режим введения для ингибиторов взаимодействия hdm2 с p53

Country Status (18)

Country Link
US (1) US10966978B2 (ru)
EP (1) EP3541387B1 (ru)
JP (1) JP6890659B2 (ru)
KR (1) KR102325778B1 (ru)
CN (2) CN115252786A (ru)
AU (1) AU2017362040C1 (ru)
CA (1) CA3043004A1 (ru)
DK (1) DK3541387T3 (ru)
ES (1) ES2880149T3 (ru)
HU (1) HUE055509T2 (ru)
IL (1) IL266171B (ru)
MX (1) MX388093B (ru)
PL (1) PL3541387T3 (ru)
PT (1) PT3541387T (ru)
RU (1) RU2762573C2 (ru)
SI (1) SI3541387T1 (ru)
TW (1) TWI757367B (ru)
WO (1) WO2018092020A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
ES2880149T3 (es) 2016-11-15 2021-11-23 Novartis Ag Dosis y régimen para inhibidores de la interacción HDM2-p53
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるhdm2−p53相互作用阻害剤の用量およびレジメン
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂,及其制备方法、药物组合物和应用
JP7653907B2 (ja) * 2018-10-30 2025-03-31 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド p53WT腫瘍の処置の方法
WO2020128894A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
WO2020262974A1 (ko) 2019-06-27 2020-12-30 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
KR20210038366A (ko) * 2019-09-30 2021-04-07 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021211819A1 (en) * 2020-04-16 2021-10-21 Albert Einstein College Of Medicine Inhibition of bax-mediated cell death by eltrombopag
EP4547201A4 (en) * 2022-07-01 2025-10-29 Jjr&D Llc METHOD FOR THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED ALOPECIA

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
PE20140408A1 (es) * 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8815926B2 (en) * 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
RS60142B1 (sr) 2013-12-05 2020-05-29 Hoffmann La Roche Novi kombinovani tretman za akutnu mijeloidnu leukemiju (aml)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
AU2016215035A1 (en) 2015-02-06 2017-09-28 Buck Institute For Research On Aging Compounds and uses in treatment of senescence-associated conditions
CN107921028A (zh) 2015-08-14 2018-04-17 诺华股份有限公司 治疗葡萄膜黑素瘤的mdm2抑制剂
ES2880149T3 (es) 2016-11-15 2021-11-23 Novartis Ag Dosis y régimen para inhibidores de la interacción HDM2-p53
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるhdm2−p53相互作用阻害剤の用量およびレジメン

Also Published As

Publication number Publication date
PT3541387T (pt) 2021-07-14
IL266171B (en) 2021-12-01
TWI757367B (zh) 2022-03-11
DK3541387T3 (da) 2021-07-19
KR102325778B1 (ko) 2021-11-12
SI3541387T1 (sl) 2021-08-31
WO2018092020A1 (en) 2018-05-24
PL3541387T3 (pl) 2021-10-25
EP3541387A1 (en) 2019-09-25
RU2762573C2 (ru) 2021-12-21
CA3043004A1 (en) 2018-05-24
MX2019005623A (es) 2019-08-14
AU2017362040C1 (en) 2020-09-10
JP2020500190A (ja) 2020-01-09
US10966978B2 (en) 2021-04-06
EP3541387B1 (en) 2021-04-21
CN115252786A (zh) 2022-11-01
TW201822817A (zh) 2018-07-01
ES2880149T3 (es) 2021-11-23
AU2017362040B2 (en) 2020-04-30
IL266171A (en) 2019-06-30
HUE055509T2 (hu) 2021-12-28
KR20190084292A (ko) 2019-07-16
MX388093B (es) 2025-03-19
RU2019118261A (ru) 2020-12-17
AU2017362040A1 (en) 2019-05-02
CN109982702A (zh) 2019-07-05
US20190298719A1 (en) 2019-10-03
JP6890659B2 (ja) 2021-06-18

Similar Documents

Publication Publication Date Title
RU2019118261A3 (ru)
CN303629227S (ru)
CN303536549S (ru)
CN303538783S (ru)
CN303538757S (ru)
CN303538746S (ru)
CN303538695S (ru)
CN303538594S (ru)
CN303538530S (ru)
CN303538471S (ru)
CN303538457S (ru)
CN303538170S (ru)
CN303702235S (ru)
CN303686746S (ru)
CN303660921S (ru)
CN303538021S (ru)
CN303641606S (ru)
CN303629428S (ru)
CN303629370S (ru)
CN303618031S (ru)
CN303605121S (ru)
CN303538000S (ru)
CN303537800S (ru)
CN303537770S (ru)
CN303537608S (ru)